University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Anatoly Urisman, MD, PhD

Anatoly Urisman, MD, PhD

Assistant Professor, Department of Pathology, UCSF

Cancer Center Program Memberships

Experimental Therapeutics

Research Summary

My research is focused on understanding regulation of cell signaling by post-tranlational modifications in cancer cells. Specifically, we are using targeted proteomic techniques to study phosphorylation dynamics in key signaling networks such as EGFR, RAS/ERK, and AKT/mTOR. The studies are aimed at identifying key regulatory phosphorylation sites relevant to tumor development, progression, response to targeted therapies, and development of resistance. As part of this effort, we are working on novel approaches for quantifying site-specific phosphorylation of low-abundance proteins, such as transcription factors and other nuclear targets of the intracellular signal transduction pathways.

Education

University of California, Berkeley, B.A., 05/1999, Molecular and Cell Biology
University of California, San Francisco, PhD, 06/2006, Biomedical Sciences
University of California, San Francisco, MD, 05/2008, Medicine, Medical Scientist Training Program
University of California, San Francisco, Residency, 7/08-6/10, Anatomic Pathology
University of California, San Francisco, Fellowship, 7/10-6/11, Pulmonary and Surgical Pathology
University of California, San Francisco, Chief Resident, 7/10-6/11, Anatomic Pathology
University of California, San Francisco, Post-doc, 7/11-6/16, Biology of lung cancer
University of California, San Francisco, Post-doc, 7/11-6/16, Proteomics of signaling


Professional Experience

  • 2008 – 2010
    Resident, Anatomic Pathology, UCSF
  • 2010 – 2011
    Chief Resident, Anatomic Pathology, UCSF
  • 2010 – 2011
    Pulmonary Pathology Fellow, Dept. of Pathology, UCSF
  • 2011 – 2014
    Research Fellow, Department of Pathology, UCSF
  • 2014 – pres.
    Clinical Instructor, Department of Pathology, UCSF
  • 2015 – pres.
    Staff Pathologist, San Francisco Veteran’s Administration Medical Center, San Francisco, CA

Selected Publications

  1. Miao J, Kyoyama H, Liu L, Chan G, Wang Y, Urisman A, Yang YL, Liu S, Xu Z, Bin H, Li H, Jablons DM, You L. Inhibition of cyclin-dependent kinase 7 down-regulates yes-associated protein expression in mesothelioma cells. J Cell Mol Med. 2019 Nov 21.
    View on PubMed
  2. J. Rotow, A. Urisman, C. Mccoach, T. Jahan, T. Bivona, K. Jones, A. Gupta, H. Do, J. Riess, D. Aisner, R. Doebele, D. Jablons, J. Kratz, C. Blakely. P1.14-58 A Phase II Study to Evaluate Neoadjuvant Osimertinib for Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 2019 Oct 1; 14(10):s578.
    View on PubMed
  3. Wang VE, Xue JY, Frederick DT, Cao Y, Lin E, Wilson C, Urisman A, Carbone DP, Bernards R, Lito P, Settleman J, McCormick F, Flaherty KT. Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors Through Autocrine FGFR Pathway Activation. Clin Cancer Res. 2019 Sep 12.
    View on PubMed
  4. Hsu PC, Tian B, Yang YL, Wang YC, Liu S, Urisman A, Yang CT, Xu Z, Jablons DM, You L. Cucurbitacin E inhibits the Yes-associated protein signaling pathway and suppresses brain metastasis of human non-small cell lung cancer in a murine model. Oncol Rep. 2019 Aug; 42(2):697-707.
    View on PubMed
  5. DeQuattro K, Urisman A, Margaretten M. A 36-Year-Old Man With Renal Failure, Fever, and Hypocomplementemia. Arthritis Care Res (Hoboken). 2019 Apr; 71(4):449-455.
    View on PubMed
  6. Castel P, Cheng A, Cuevas-Navarro A, Everman DB, Papageorge AG, Simanshu DK, Tankka A, Galeas J, Urisman A, McCormick F. RIT1 oncoproteins escape LZTR1-mediated proteolysis. Science. 2019 03 15; 363(6432):1226-1230.
    View on PubMed
  7. Wong AW, Urisman A, Burlingame AL, Shokat KM. Chemically reprogramming the phospho-transfer reaction to crosslink protein kinases to their substrates. Protein Sci. 2019 Mar; 28(3):654-662.
    View on PubMed
  8. Rotow JK, Woodard GA, Urisman A, McCoach CE, Bivona TG, Elicker BM, Jablons DM, Blakely CM. Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation. Clin Lung Cancer. 2019 03; 20(2):e137-e141.
    View on PubMed
  9. Hung LY, Sen D, Oniskey TK, Katzen J, Cohen NA, Vaughan AE, Nieves W, Urisman A, Beers MF, Krummel MF, Herbert DR. Macrophages promote epithelial proliferation following infectious and non-infectious lung injury through a Trefoil factor 2-dependent mechanism. Mucosal Immunol. 2019 01; 12(1):64-76.
    View on PubMed
  10. Sahoo PK, Lee SJ, Jaiswal PB, Alber S, Kar AN, Miller-Randolph S, Taylor EE, Smith T, Singh B, Ho TS, Urisman A, Chand S, Pena EA, Burlingame AL, Woolf CJ, Fainzilber M, English AW, Twiss JL. Axonal G3BP1 stress granule protein limits axonal mRNA translation and nerve regeneration. Nat Commun. 2018 08 22; 9(1):3358.
    View on PubMed
  11. Ramirez JL, Urisman A, Kukreja J, Kratz JR. Surgical Management of Pulmonary Mucormycosis in Third-Trimester Pregnancy. Thorac Cardiovasc Surg Rep. 2018 Jan; 7(1):e27-e29.
    View on PubMed
  12. Hsu PC, Miao J, Huang Z, Yang YL, Xu Z, You J, Dai Y, Yeh CC, Chan G, Liu S, Urisman A, Yang CT, Jablons DM, You L. Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model. J Cell Mol Med. 2018 06; 22(6):3073-3085.
    View on PubMed
  13. Terenzio M, Koley S, Samra N, Rishal I, Zhao Q, Sahoo PK, Urisman A, Marvaldi L, Oses-Prieto JA, Forester C, Gomes C, Kalinski AL, Di Pizio A, Doron-Mandel E, Perry RB, Koppel I, Twiss JL, Burlingame AL, Fainzilber M. Locally translated mTOR controls axonal local translation in nerve injury. Science. 2018 03 23; 359(6382):1416-1421.
    View on PubMed
  14. Forester CM, Zhao Q, Phillips NJ, Urisman A, Chalkley RJ, Oses-Prieto JA, Zhang L, Ruggero D, Burlingame AL. Revealing nascent proteomics in signaling pathways and cell differentiation. Proc Natl Acad Sci U S A. 2018 03 06; 115(10):2353-2358.
    View on PubMed
  15. Kirk D. Jones, Anatoly Urisman. Chapter 12 Histopathologic Approach to the Surgical Lung Biopsy in Interstitial Lung Disease. Interstitial Lung Disease. 2018 Jan 1; 141-155.
    View on PubMed
  16. Wang VE, Urisman A, Albacker L, Ali S, Miller V, Aggarwal R, Jablons D. Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden. J Immunother Cancer. 2017 09 19; 5(1):75.
    View on PubMed
  17. Wang VE, Young L, Ali S, Miller VA, Urisman A, Wolfe J, Bivona TG, Damato B, Fogh S, Bergsland EK. A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases. Oncologist. 2017 07; 22(7):768-773.
    View on PubMed
  18. Wang P, Jones KD, Urisman A, Elicker BM, Urbania T, Johannson KA, Assayag D, Lee J, Wolters PJ, Collard HR, Koth LL. Pathologic Findings and Prognosis in a Large Prospective Cohort of Chronic Hypersensitivity Pneumonitis. Chest. 2017 09; 152(3):502-509.
    View on PubMed
  19. Brownell R, Moua T, Henry TS, Elicker BM, White D, Vittinghoff E, Jones KD, Urisman A, Aravena C, Johannson KA, Golden JA, King TE, Wolters PJ, Collard HR, Ley B. The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia. Thorax. 2017 May; 72(5):424-429.
    View on PubMed
  20. Anatoly Urisman, Zoltan G. Laszik. Infection-Associated Thrombotic Microangiopathy. Bacterial Infections and the Kidney. 2017 Jan 1; 135-159.
    View on PubMed

Go to UCSF Profiles, powered by CTSI